Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment

NCT07287852 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT07287852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07287852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment
Lead sponsor
Hadassah Medical Organization
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
August 20, 2024
Completion date
December 31, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease (ad), mild cognitive impairment (mci)